Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01370265 |
Recruitment Status
:
Completed
First Posted
: June 9, 2011
Results First Posted
: September 5, 2013
Last Update Posted
: September 5, 2013
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Coronary Artery Disease | Drug: Regadenoson Drug: Adenosine Drug: N-13 ammonia | Not Applicable |
The hypothesis for this study was that Regadenoson will produce a very similar degree of maximal hyperemia (increased blood flow) as adenosine, the other vasodilator agent. There were only 2 days on study for each subject.
On Day 1 of the study, subjects were interviewed and had a physical exam, including a resting 12-lead electrocardiogram (ECG) to exclude evidence of silent ischemia or myocardial infarction, and other cardiovascular disorders. Subjects were instructed to have a light meal at least 4 hours prior to the PET MPI. Subjects were instructed to abstain from caffeine-containing products for 24 hours prior to the PET scan. Day 1 of the study occurred less than or equal to 4 weeks of Day 2.
On Day 2 of the study, each subject underwent three PET N-13 ammonia (10-20 mCi) dynamic emission acquisitions: resting, regadenoson (0.4 mg/5 mL IV), and adenosine (140 microgram/kg/min; order of regadenoson vs adenosine was randomized according to subject's birth year), and three transmission acquisitions for attenuation correction. Each emission acquisition was separated by 50 min to allow for radioactive decay. At the end of the drug infusions, subjects were monitored for 5-30 min. Based on the known short biological half-lives of these stress agents, the pharmacologic effects of each drug should have dissipated by the time the next drug was administered.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 12 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Quantification of Myocardial Blood Flow by Positron Emission Tomography and N-13 Ammonia During Regadenoson vs Adenosine Stress |
Study Start Date : | February 2011 |
Actual Primary Completion Date : | February 2012 |
Actual Study Completion Date : | June 2012 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Regadenoson, then Adenosine
Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the first intervention period. Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the second intervention period (after washout period). Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered.
|
Drug: Regadenoson
Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush.
Other Name: Lexiscan
Drug: Adenosine
Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.
Other Name: Adenoscan
Drug: N-13 ammonia
Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. The N-13 ammonia used in the study was synthesized by the Mayo Cyclotron Facility as per routine institutional clinical protocol.
|
Active Comparator: Adenosine, then Regadenoson
Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the first intervention period. Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered. After a washout period, Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the second intervention period.
|
Drug: Regadenoson
Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush.
Other Name: Lexiscan
Drug: Adenosine
Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.
Other Name: Adenoscan
Drug: N-13 ammonia
Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. The N-13 ammonia used in the study was synthesized by the Mayo Cyclotron Facility as per routine institutional clinical protocol.
|
- Global Hyperemic Myocardial Blood Flow (MBF) [ Time Frame: Day 2, approximately 4 hours after arrival in positron emission tomography (PET) unit ]
MBF is the rate of blood supplied to the myocardium, or heart muscle. Hyperemic MBF is the rate of myocardial blood flow in the heart muscle during either regadenoson or adenosine stress. Myocardial blood flow was calculated using commercial software (PMOD Technologies, version 2.4).
The Hyperemic MBF was measured approximately 4 hours after arrival in the PET unit.
- Resting Global MBF and Resting Segmental MBF [ Time Frame: Day 2, approximately 35 minutes after arrival in positron emission tomography (PET) unit ]
MBF is the rate of blood supplied to the myocardium, or heart muscle. Global Myocardial blood flow was calculated using commercial software (PMOD Technologies, version 2.4).
Regional MBFs were calculated using commercial software (PMOD Technologies, version 2.4). After the apical and basal slices of the left ventricular myocardium were chosen, the software automatically defined 4 myocardial regions of interest (segments) in the apical planes.
- Global Cardiac Flow Rate [ Time Frame: Day 2, approximately 4 hours after arrival in positron emission tomography (PET) unit ]Cardiac Flow Rate was calculated using the equation: hyperemic MBF/resting MBF.
- Hyperemic Segmental MBF [ Time Frame: Day 2, approximately 4 hours after arrival in positron emission tomography (PET) unit ]
Regional MBFs were calculated using commercial software (PMOD Technologies, version 2.4). After the apical and basal slices of the left ventricular myocardium were chosen, the software automatically defined 4 myocardial regions of interest (segments) in the apical planes.
The hyperemic MBF was measured approximately 4 hours after arrival in the PET unit, depending on the randomization.
- Segmental CFR [ Time Frame: Day 2, approximately 4 hours after arrival in positron emission tomography (PET) unit ]CFR was calculated using the equation: hyperemic MBF/resting MBF.
- Heart Rate (Beats Per Minute (BPM)) [ Time Frame: Day 2, approximately 35 minutes and approximately 4 hours after arrival in the PET unit ]The resting heart rate was measured approximately 35 minutes after arrival in the PET unit. The hyperemic heart rate was measured approximately 4 hours after arrival in the PET unit, depending on the randomization.
- Hyperemic Blood Pressure (mmHg) [ Time Frame: Day 2, approximately 4 hours after arrival in the PET unit ]Blood pressure was measured approximately 4 hours after arrival in the PET unit, depending on the randomization.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 30 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy male and female volunteers over the age of 30.
- Written informed consent will be obtained from each subject.
- Each subject will undergo a history and physical examination
Exclusion Criteria:
- Any cardiovascular or pulmonary symptoms or exam findings
- History of low blood pressure (< 90/50 mmHg)
- Prior cardiac history
- History of hypertension
- History of hyperlipidemia
- History of diabetes mellitus
- History of asthma or chronic obstructive pulmonary disease
- Weight of > 450 pounds
- Chronic kidney disease
- Other serious illness such as cancer
- Current smoking
- Medication use (with the exception of acetaminophen, aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and thyroid hormone replacement)
- Illicit drug use
- Prior allergic reaction to adenosine, regadenoson, or aminophylline
- Pregnancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01370265
United States, Minnesota | |
Mayo Clinic | |
Rochester, Minnesota, United States, 55905 |
Principal Investigator: | Panithaya Chareonthaitawee, M.D. | Mayo Clinic |
Responsible Party: | Panithaya Chareonthaitawee, Consultant, Associate Professor, Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT01370265 History of Changes |
Other Study ID Numbers: |
10-006377 |
First Posted: | June 9, 2011 Key Record Dates |
Results First Posted: | September 5, 2013 |
Last Update Posted: | September 5, 2013 |
Last Verified: | September 2013 |
Keywords provided by Panithaya Chareonthaitawee, Mayo Clinic:
Regadenoson (Lexiscan) PET N-13 ammonia imaging Myocardial Blood Flow (MBF) Regadenoson Stress |
Additional relevant MeSH terms:
Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Adenosine Regadenoson Analgesics |
Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Arrhythmia Agents Vasodilator Agents Purinergic P1 Receptor Agonists Purinergic Agonists Purinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adenosine A2 Receptor Agonists |